Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Account Payables (2019 - 2025)

Allogene Therapeutics' Change in Account Payables history spans 7 years, with the latest figure at -$1.1 million for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 85.17% year-over-year to -$1.1 million; the TTM value through Sep 2025 reached -$1.8 million, down 114.06%, while the annual FY2024 figure was -$503000.0, 93.3% up from the prior year.
  • Change in Account Payables for Q3 2025 was -$1.1 million at Allogene Therapeutics, down from -$422000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.8 million in Q2 2024 and bottomed at -$7.2 million in Q3 2024.
  • The 5-year median for Change in Account Payables is -$302000.0 (2023), against an average of -$301789.5.
  • The largest YoY upside for Change in Account Payables was 497.7% in 2021 against a maximum downside of 666.36% in 2021.
  • A 5-year view of Change in Account Payables shows it stood at -$2.0 million in 2021, then skyrocketed by 243.74% to $2.9 million in 2022, then plummeted by 110.28% to -$302000.0 in 2023, then skyrocketed by 111.26% to $34000.0 in 2024, then tumbled by 3252.94% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Change in Account Payables are -$1.1 million (Q3 2025), -$422000.0 (Q2 2025), and -$336000.0 (Q1 2025).